Updates are available Correction dated 2024-09-03
Click to view Correction: https://doi.org/10.1186/s13052-024-01719-5
-
Authors
Cutrera, Renato http://orcid.org/0000-0001-7711-5672
d’Angela, Daniela http://orcid.org/0000-0003-3409-4757
Orso, Massimiliano http://orcid.org/0000-0003-0200-1202
Guadagni, Liliana http://orcid.org/0000-0003-0156-1742
Vittucci, Anna Chiara http://orcid.org/0000-0002-1164-5563
Bertoldi, Ilaria
Polistena, Barbara http://orcid.org/0000-0002-0138-0223
Spandonaro, Federico http://orcid.org/0000-0003-1388-2850
Carrieri, Ciro http://orcid.org/0000-0002-7086-0327
Montuori, Eva Agostina http://orcid.org/0009-0002-8045-8312
Iantomasi, Raffaella http://orcid.org/0000-0003-2101-2476
Orfeo, Luigi
-
Funding
Funding for this research was provided by:
Pfizer Italia (Pfizer Italia)
- License Information
-
More Information
Article History
Received: 26 January 2024
Accepted: 8 June 2024
First Online: 21 June 2024
Change Date: 3 September 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13052-024-01719-5
Declarations
:
: Ethical approval and patients’ informed consent for this study were not required because only anonymized data were used.
: Not applicable.
: RC, ACV, LO were paid consultants to Pfizer in connection with the development of this manuscript. ACV participated at advisory board sponsored by Sanofi. RI, IB and EAM are employees of Pfizer and may hold Pfizer stock or stock options. BP has received payments or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from the following commercial sources: Allergan, Amgen, Astellas, Baxter, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Janssen Cilag, Jazzpharma, Mylan, Nestlé HS, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Servier, Shire, Takeda, Teva; in addition, she received consulting fees from UCB. FS has received payments or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from the following commercial sources: Allergan, Amgen, Astellas, Baxter, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Janssen Cilag, Jazzpharma, Mylan, Nestle´HS, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Servier, Shire, Takeda, Teva; in addition, he received consulting fees from Amgen. All other authors declare that they have no competing interests.
